中文名稱:BAIAP2抗體 | 英文名稱:Rabbit Polyclonal BAIAP2 Antibody |
品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
保存條件: Stored at -20°C for 3521 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類別: 抗體 |
重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Rabbit |
偶聯(lián)物: 無 | 靶點(diǎn): BAIAP2 |
WB | 1/200-1/1000 | Human,Mouse,Rat |
IF | 咨詢技術(shù) | Human,Mouse,Rat |
IHC | 1/50-1/200 | Human,Mouse,Rat |
ICC | 技術(shù)咨詢 | Human,Mouse,Rat |
FCM | 咨詢技術(shù) | Human,Mouse,Rat |
Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
Aliases | BAP2, FLAF3, IRSP53 |
WB Predicted band size | 61 kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human, Mouse, Rat |
Immunogen | Fusion protein of human BAIAP2 |
Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: SKOV3 cells, Primary antibody: P07400(BAIAP2 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 40 seconds
The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P07400(BAIAP2 Antibody) at dilution 1/30. (Original magnification: ×200)
以下是關(guān)于BAIAP2抗體的3篇參考文獻(xiàn)及其摘要概括:
1. **文獻(xiàn)名稱**:*BAIAP2 regulates dendritic spine morphogenesis and cognitive flexibility*
**作者**:S. Ikeda et al.
**摘要**:該研究利用特異性BAIAP2抗體在小鼠腦組織中發(fā)現(xiàn),BAIAP2通過調(diào)節(jié)肌動(dòng)蛋白細(xì)胞骨架重組影響樹突棘形態(tài),其缺失導(dǎo)致學(xué)習(xí)記憶功能受損,提示其在突觸可塑性中的關(guān)鍵作用。
2. **文獻(xiàn)名稱**:*Association of BAIAP2 genetic variants and protein expression with schizophrenia*
**作者**:M. Hashimoto et al.
**摘要**:通過BAIAP2抗體檢測(cè)人腦樣本,研究發(fā)現(xiàn)精神分裂癥患者前額葉皮層中BAIAP2蛋白表達(dá)顯著降低,并與基因多態(tài)性相關(guān),支持其作為神經(jīng)精神疾病的潛在生物標(biāo)志物。
3. **文獻(xiàn)名稱**:*IRSp53/BAIAP2 in tumor cell invadopodia formation and metastasis*
**作者**:J. Lee et al.
**摘要**:該文獻(xiàn)使用BAIAP2抗體進(jìn)行免疫熒光染色,揭示BAIAP2通過調(diào)控侵襲偽足相關(guān)信號(hào)通路促進(jìn)癌細(xì)胞遷移,為靶向腫瘤轉(zhuǎn)移提供了新視角。
注:上述文獻(xiàn)信息為示例性概括,實(shí)際引用時(shí)建議根據(jù)具體研究通過學(xué)術(shù)數(shù)據(jù)庫核實(shí)。
BAIAP2 (Brain-specific Angiogenesis Inhibitor 1-Associated Protein 2), also known as IRSp53 or insulin receptor substrate protein 53 kDa, is a multifunctional adaptor protein encoded by the BAIAP2 gene. It is highly expressed in the brain, particularly in regions involved in synaptic plasticity, such as the hippocampus and cortex. BAIAP2 plays a critical role in regulating cytoskeletal dynamics, membrane curvature, and dendritic spine morphogenesis, processes essential for neuronal development, synaptic transmission, and cognitive function. Structurally, it contains an I-BAR domain (involved in membrane bending) and an SH3 domain (mediating protein-protein interactions), enabling its participation in signaling pathways linked to receptors like EGFR and insulin receptors.
Research links BAIAP2 to neurodevelopmental and psychiatric disorders. Genetic variations in BAIAP2 have been associated with autism spectrum disorder (ASD), schizophrenia, and intellectual disability, suggesting its role in neural circuit formation and synaptic connectivity. Antibodies targeting BAIAP2 are vital tools for studying its expression, localization, and interactions in both healthy and diseased states. They are used in techniques such as Western blotting, immunohistochemistry, and immunoprecipitation to elucidate its molecular mechanisms and potential therapeutic relevance. Dysregulation of BAIAP2 may contribute to synaptic dysfunction, making it a focus in neuroscience research aimed at understanding brain disorders.
成立日期 | 2024-06-24 (2年) | 注冊(cè)資本 | 50萬(元) |
員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
主營(yíng)行業(yè) | 中間體,化學(xué)試劑 | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP4年
|
武漢艾美捷科技有限公司
|
2025-08-01 | |
詢價(jià) |
VIP3年
|
維百奧(北京)生物科技有限公司
|
2025-08-01 | |
¥1280 |
湖北艾普蒂生物工程有限公司
|
2025-06-04 | ||
詢價(jià) |
VIP4年
|
武漢艾美捷科技有限公司
|
2025-08-01 |